Core Viewpoint - Texas Attorney General Ken Paxton has filed a lawsuit against Kenvue, alleging that the company concealed important information, and is seeking to block a nearly $400 million shareholder dividend payment scheduled for this month [1] Company Summary - Kenvue is facing legal action from the Texas Attorney General, which could impact its financial decisions, particularly regarding the planned dividend payout [1] - The lawsuit claims that Kenvue has not been transparent about certain issues, raising concerns among shareholders and regulators [1] Industry Summary - The legal challenges faced by Kenvue may reflect broader regulatory scrutiny within the pharmaceutical industry, particularly regarding corporate governance and financial disclosures [1] - The potential blocking of the dividend payment could set a precedent for how similar cases are handled in the industry, influencing investor confidence and market behavior [1]

Core Viewpoint - Kenvue shares experienced a recovery of over 5% in premarket trading after hitting a record low, following comments made by US President Donald Trump regarding the company's popular pain relief product [1] Group 1 - Kenvue's stock price rose more than 5% in premarket trading on Tuesday [1] - The increase in share price comes after the company reached a record low in the previous session [1] - US President Donald Trump's remarks linked to Kenvue's pain relief product contributed to the recovery in stock price [1]